RadNet AI Subsidiary Aidence Collaborated with Google Health to Improve Lung Cancer Screening Using AI Solutions
Shots:
- Aidence, a RadNet AI subsidiary collaborated with Google Health to license Google Health’s AI research model for lung nodule malignancy prediction on CT imaging
- Aidence will be responsible to develop, validate & market this model to support the early and accurate diagnosis of lung cancer and the reduction of unnecessary procedures in screening programs while Google Health will provide its scientific expertise.
- Based on the (NELSON) trial, lung cancer screening with low-dose CT showed a reduction in lung cancer mortality by 24% for men and 33% for women. The eligibility requirements have recently been widened in the US reflecting the benefit of lung cancer screening
Ref: Globenewswire | Image: RadNet
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
